TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

~ Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant ~ Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose ~ Expecting to Complete Phase 1 Safety and Pharmacokinetic Data of Inhaled Niclosamide by End of 1Q’22

Daniel Carlson

February 24, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

5 COMMENTS

EC2021 February 24, 2022 at 11:09 am

You need to login to view this content.

Reply
- Daniel Carlson February 24, 2022 at 6:48 pm
  
  You need to login to view this content.
  
  Reply
  - EC2021 February 24, 2022 at 7:55 pm
    
    You need to login to view this content.
    
    Reply
Peter February 24, 2022 at 10:29 am

You need to login to view this content.

Reply
- Daniel Carlson February 24, 2022 at 10:33 am
  
  You need to login to view this content.
  
  Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.